文献速递临床试验与 GCP

新辅助放化疗后行侧盆腔淋巴结清扫术治疗晚期低位直肠癌术前侧方淋巴结肿大:随机对照试验研究方案

Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2016-11-25

该前瞻性、多中心、随机对照、单盲III期试验计划纳入512例晚期直肠癌且术前侧方淋巴结肿大的患者,随机分为单纯全直肠系膜切除术组或全直肠系膜切除术加侧盆腔淋巴结清扫术组,主要结局为3年局部复发率和3年无病生存率。

要点

  • 针对术前侧方淋巴结肿大的晚期直肠癌患者,评估侧盆腔淋巴结清扫术的疗效与安全性。
  • 计划纳入512例,随机分为TME组与TME+LLND组,主要终点为3年局部复发率和3年无病生存率。
  • 次要结局包括3年总生存率、1年性功能与排尿功能及围手术期结局。

核心结论

  • 该试验旨在评估侧盆腔淋巴结清扫术对疑似侧方淋巴结转移的直肠癌患者的疗效与安全性,结果预期为晚期直肠癌疑似侧方淋巴结转移的治疗提供新证据。

研究设计与样本

  • 前瞻性、多中心、随机对照、单盲III期试验,计划纳入512例晚期直肠癌且术前侧方淋巴结肿大的合格患者。
  • 合格筛选后随机分配至单纯全直肠系膜切除术组或全直肠系膜切除术加侧盆腔淋巴结清扫术组。

主要发现

  • 主要结局为3年局部复发率和3年无病生存率。
  • 次要结局包括3年总生存率、1年性功能与排尿功能及围手术期结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lateral lymph node (LLN) metastasis is a major cause of local recurrence of advanced rectal cancer. Although there is much controversy between Western and Eastern countries on whether lateral pelvic lymph node dissection (LLND) or neoadjuvant chemo-radiation (nCRT) is preferable for the treatment of LLN metastases, existing retrospective cohorts mainly focus on all middle/low advanced rectal cancer patients, not the specific individuals with suspicion of LLN metastases. The aim of this trial is to assess the efficacy and safety of LLND for rectal cancer patients with suspicion of LLN metastases. METHODS: This prospective, multicenter, randomized controlled, single-blinded, phase III trial is designed to enroll 512 eligible patients with advanced rectal cancer and preoperative enlarged lateral lymph nodes. The population will be randomly assigned into the solely total mesorectal excision (TME) group or the TME + LLND group after eligible selection. The primary outcomes are to be 3-year local recurrence rate and 3-year disease-free survival, and the secondary outcomes include 3-year overall survival, 1-year sexual and urinary function, and perioperative outcomes. DISCUSSION: This is the first randomized trial to investigate the efficacy and safety of LLND for advanced low rectal cancer patients with suspicion of LLN metastases; the result is expected to provide new evidence for the treatment of LLN where there is suspicion of metastases in advanced rectal cancer patients. TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov (identifier NCT02614157 ) Registered on 24 November 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wei M, Wu Q, Fan C, et al. Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial. Trials. 2016. PMID: 27884204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。